Ekso Bionics to Showcase Integrated Functional Electrical Stimulation for Indego Therapy at APTA Meeting
24 February 2023 - 12:00AM
Ekso Bionics (Nasdaq: EKSO) (the “Company”), an industry leader in
exoskeleton technology for medical and industrial use, today
announced it will showcase the new Ekso Indego Therapy with
Functional Electrical Stimulation (FES) at the upcoming American
Physical Therapy Association’s Combined Sections Meeting on
February 23-25 in San Diego, California. The Company recently filed
a Premarket Notification 510(k) with the U.S. Food and Drug
Administration that covers the addition of integrated FES hardware
and software to Ekso Indego Therapy, a lower-limb powered
exoskeleton recently acquired by Ekso.
“This unique integrated solution is a testament
to Ekso Bionics’ continued commitment to innovation and delivering
on our promise of maximizing patient outcomes,” said Scott Davis,
Chief Executive Officer of Ekso Bionics. “Individuals with spinal
cord injury or stroke who use Ekso Indego Therapy in a
rehabilitation setting will soon have the opportunity to benefit
from FES in further improving limb function, balance and muscle
strength. We are excited to see the added benefits this technology
will bring to patients across the continuum of care.”
Ekso Indego Therapy with FES offers ten channels
of electrical stimulation, which can be individually connected to a
selection of muscle groups, including quadriceps, hamstrings,
gluteus maximus, tibialis anterior, gastrocnemius, trunk flexors
and trunk extensors. Ekso Indego Therapy with FES will
automatically adapt timing of stimulation to match a patient’s
speed in motion+ and advanced gait programs, and each of the ten
FES channels may be customized, allowing for individualized user
settings and therapy programs.
About Ekso Bionics®Ekso
Bionics® is a leading developer of exoskeleton solutions that
amplify human potential by supporting or enhancing strength,
endurance and mobility across medical and industrial applications.
Founded in 2005, the Company continues to build upon its
industry-leading expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only known exoskeleton company to offer technologies that range
from helping those with paralysis to stand up and walk, to
enhancing human capabilities on job sites across the globe. The
Company is headquartered in the San Francisco Bay Area and is
listed on the Nasdaq Capital Market under the symbol “EKSO.” For
more information, visit: www.eksobionics.com or follow @EksoBionics
on Twitter.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the potential benefits of the Company’s
products, including the EksoNR, (ii) the performance or
effectiveness of the Company’s products, including the EksoNR, and
(iii) the assumptions underlying or relating to any statement
described in clauses (i) and (ii) above. Such forward-looking
statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized
because they are based upon the Company’s current projections,
plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors
that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, the ongoing COVID-19 pandemic and its impact on the
Company’s financial condition and business, the highly competitive
markets in which the Company’s products are sold, the new and
unproven nature of the market for the Company’s products, the long
and variable sales cycles for the Company’s products, the factors
outside the Company’s control that affect the international sales
of its products, the costs related to and impacts of potential
failure of the Company to obtain or maintain protection for the
Company's intellectual property rights, the failure of the Company
to obtain or maintain regulatory approval to market the Company's
medical devices, and risks related to product liability, recall and
warranty claims. These and other factors are identified and
described in more detail in the Company’s filings with the U.S.
Securities and Exchange Commission. To learn more about Ekso
Bionics please visit the Company’s website at www.eksobionics.com
or follow @EksoBionics on Twitter. The Company does not undertake
to update these forward-looking statements.
Contact:David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024